Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma

(2020) S. Ugurel et al.   ANNALS OF ONCOLOGY

Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma

(2020) Minh Phuong Dong et al.   Scientific Reports

NK Cell-Based Immune Checkpoint Inhibition

(2020) Muhammad Khan et al.   Frontiers in Immunology

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

(2020) Manuela Tiako Meyo et al.   Cancers

The Role of PD-1 in Acute and Chronic Infection

(2020) Jil M. Jubel et al.   Frontiers in Immunology

Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy

(2020) Yu-e Qin et al.   Cancer Management and Research

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

(2019) Xianjie Jiang et al.   Molecular Cancer

Turning the corner on therapeutic cancer vaccines

(2019) Robert E. Hollingsworth et al.   npj Vaccines

Progress in EBV Vaccines

(2019) Dwain G. van Zyl et al.   Frontiers in Oncology

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

(2019) Benjamin Bian et al.   OncoImmunology

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

(2019) Tetsuro Tominaga et al.   PLoS One

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

(2019) Bo Gong et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combination therapies with HSP90 inhibitors against colorectal cancer

(2019) Kushtrim Kryeziu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.

(2019) Woochan Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy

(2019) Yanyun Ruan et al.   Biomed Research International

Recent advances in the clinical development of immune checkpoint blockade therapy

(2019) Atefeh Ghahremanloo et al.   CELLULAR ONCOLOGY

Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system

(2019) Claire Lhuillier et al.   Genome Medicine

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

(2019) Xiangfeng Shen et al.   Frontiers in Immunology

The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer

(2019) Takeo Shibata et al.   CANCER TREATMENT REVIEWS

Dual Arms of Adaptive Immunity: Division of Labor and Collaboration between B and T Cells

(2019) K. Christopher Garcia   CELL

The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer

(2019) Taher Abu Hejleh et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma

(2018) Furong Liu et al.   BULLETIN DU CANCER

Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer

(2018) Zehong Chen et al.   CANCER SCIENCE

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer

(2018) Yusuke Okuma et al.   Clinical Lung Cancer

Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer

(2018) Masahiro Takeuchi et al.   IMMUNOLOGY LETTERS

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Cytokines in the Treatment of Cancer

(2018) Kevin C. Conlon et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels

(2018) LiJun Xu et al.   Molecular Oncology

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy

(2018) Hyun Ju Kim et al.   RADIOTHERAPY AND ONCOLOGY

Defining and Understanding Adaptive Resistance in Cancer Immunotherapy

(2018) Tae Kon Kim et al.   TRENDS IN IMMUNOLOGY

The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence

(2018) Siew-Min Ong et al.   Cell Death & Disease

Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers

(2018) Stephanie Dorta-Estremera et al.   CANCER RESEARCH

Genomic characterization of six virus-associated cancers identifies changes in the tumor immune microenvironment and altered genetic programs

(2018) Frederick S. Varn et al.   CANCER RESEARCH

SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases

(2018) Muhammad Khan et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

NKX2-1-AS1 negatively regulates CD274/PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration

(2018) Hasmeena Kathuria et al.   Scientific Reports

Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression

(2018) Tsunehiko Shigemori et al.   ANNALS OF SURGICAL ONCOLOGY

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma

(2018) Boyang Chang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Regulation of immune responses by E3 ubiquitin ligase Cbl-b

(2018) Rong Tang et al.   CELLULAR IMMUNOLOGY

Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis

(2018) Marcelo Bonomi et al.   Oncology Letters

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-Oncology

(2018) Hyerim Ha et al.   Cancer Research and Treatment

Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis—a pilot study

(2018) Dragana Jovanovic et al.   Journal of Thoracic Disease

Soluble immune checkpoints in cancer: production, function and biological significance

(2018) Daqian Gu et al.   Journal for ImmunoTherapy of Cancer

MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells

(2017) Daniel Yee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer

(2017) Yusuke Okuma et al.   LUNG CANCER

Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy

(2017) Jing Zhao et al.   MEDICINE

Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer

(2017) Emeka K Enwere et al.   MODERN PATHOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells

(2017) Gengchen Xie et al.   PLoS One

Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients

(2017) Richard Linedale et al.   PLoS One

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

(2017) Krzysztof M. Zak et al.   STRUCTURE

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

(2017) Rina M. Mbofung et al.   Nature Communications

Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway

(2017) Ming Jing Shen et al.   Oncotarget

Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection

(2017) Na Li et al.   Oncotarget

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

(2017) Xinxin Zhu et al.   Oncotarget

Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting

(2017) Jennifer Peyling Wang et al.   Journal of Cancer

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

(2017) Jun Zhou et al.   Cancer Immunology Research

A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers

(2017) Po-Lin Lin et al.   Cancer Medicine

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab

(2017) Greta Garrido et al.   Frontiers in Pharmacology

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

(2017) Stephan Kruger et al.   OncoImmunology

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

(2017) Zibing Wang et al.   OncoImmunology

CD28 Costimulation: From Mechanism to Therapy

(2016) Jonathan H. Esensten et al.   IMMUNITY

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

(2016) Frank A. Schildberg et al.   IMMUNITY

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The immune system and cancer evasion strategies: therapeutic concepts

(2016) S. Muenst et al.   JOURNAL OF INTERNAL MEDICINE

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib

(2016) Steffen Filskov Sorensen et al.   LUNG CANCER

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis

(2016) Kristian Aarslev et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity

(2016) Xiao-Ping Wang et al.   Oncotarget

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

(2016) Hyerim Ha et al.   Oncotarget

PD-1 and its ligands are important immune checkpoints in cancer

(2016) Yinan Dong et al.   Oncotarget

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

(2016) Sarah Derks et al.   Oncotarget

A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice

(2016) Zhida Liu et al.   OncoImmunology

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

(2016) E. Liniker et al.   OncoImmunology

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression

(2015) A E Rice et al.   CANCER GENE THERAPY

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways

(2015) Cuiping Liu et al.   ARTHRITIS RESEARCH & THERAPY

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

IL-27 induces the expression of IDO and PD-L1 in human cancer cells

(2015) Grazia Carbotti et al.   Oncotarget

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients

(2015) R. M. Srivastava et al.   Cancer Immunology Research

Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy

(2015) D. A. Proia et al.   Cancer Immunology Research

Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses

(2015) Wei-Bei Wang et al.   Stem Cell Reports

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

IL-12 Regulates B7-H1 Expression in Ovarian Cancer-associated Macrophages by Effects on NF-κB Signalling

(2014) Hai-Yu Xiong et al.   Asian Pacific Journal of Cancer Prevention

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes

(2014) A.-Y. Gong et al.   JOURNAL OF IMMUNOLOGY

STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells

(2014) J. W. Austin et al.   JOURNAL OF IMMUNOLOGY

Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity

(2014) K Dodd et al.   ONCOGENE

Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma

(2014) Hsiang-Yun Cheng et al.   PLoS One

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Upregulated PD-1 Expression Is Associated with the Development of Systemic Lupus Erythematosus, but Not the PD-1.1 Allele of the PDCD1 Gene

(2014) Qingqing Jiao et al.   International Journal of Genomics

Metabolic Regulation of T Lymphocytes

(2013) Nancie J. MacIver et al.   Annual Review of Immunology

Reconstructed Adeno-Associated Virus with the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity

(2013) Osama A.O. Elhag et al.   Asian Pacific Journal of Cancer Prevention

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma

(2013) Weipeng Wang et al.   HUMAN GENETICS

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia

(2013) Wen Yang et al.   IMMUNOLOGY

In Vivo Blockade of the Programmed Cell Death-1 Pathway Using Soluble Recombinant PD-1-Fc Enhances CD4+ and CD8+ T Cell Responses but Has Limited Clinical Benefit

(2013) P. K. Amancha et al.   JOURNAL OF IMMUNOLOGY

Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells

(2013) Anke Jaudszus et al.   JOURNAL OF LIPID RESEARCH

PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

(2013) Nikolaos Patsoukis et al.   MOLECULAR AND CELLULAR BIOLOGY

Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response

(2013) Seung-Pil Shin et al.   MOLECULAR THERAPY

Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy

(2013) JINBAO ZONG et al.   ONCOLOGY REPORTS

Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis

(2013) SR Greisen et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

(2013) Mario Roselli et al.   OncoImmunology

Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein

(2012) C. A. Crane et al.   CLINICAL CANCER RESEARCH

Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti- Tumor Responses

(2012) T.E. Schmid et al.   CURRENT MEDICINAL CHEMISTRY

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

(2012) John Dulos et al.   JOURNAL OF IMMUNOTHERAPY

Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies

(2012) Carlos A. Ramos et al.   JOURNAL OF IMMUNOTHERAPY

Gene therapy for brain tumors: Basic developments and clinical implementation

(2012) Hikmat Assi et al.   NEUROSCIENCE LETTERS

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma

(2012) XIU-CHENG PAN et al.   Oncology Letters

E3 Ubiquitin Ligase Cbl-b Regulates Pten via Nedd4 in T Cells Independently of Its Ubiquitin Ligase Activity

(2012) Hui Guo et al.   Cell Reports

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

(2012) Laurence Zitvogel et al.   OncoImmunology

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro

(2011) N Etminan et al.   BRITISH JOURNAL OF CANCER

Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

(2011) X. Frigola et al.   CLINICAL CANCER RESEARCH

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells

(2011) Katarzyna Karwacz et al.   EMBO Molecular Medicine

IFN-  Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

(2011) S. Terawaki et al.   JOURNAL OF IMMUNOLOGY

Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1

(2011) Mi-Young Song et al.   JOURNAL OF IMMUNOTHERAPY

Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells

(2010) Daniel Abate-Daga et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: Granulocyte-Macrophage Colony-Stimulating Factor Is the Major CD8+ T Cell-Derived Licensing Factor for Dendritic Cell Activation

(2010) L. Min et al.   JOURNAL OF IMMUNOLOGY

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

(2010) Michael Quigley et al.   NATURE MEDICINE

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

(2010) H.-T. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection

(2010) Florence Faurez et al.   VACCINE

T Cell Activation

(2009) Jennifer E. Smith-Garvin et al.   Annual Review of Immunology

Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70

(2009) Yufeng Xie et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use

(2009) Jianlin Gong et al.   JOURNAL OF IMMUNOLOGY

Papillomaviruses in the causation of human cancers — a brief historical account

(2009) Harald zur Hausen   VIROLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Recombinant CBD–HepII polypeptide of fibronectin inhibits αvβ3 signaling and hematogenous metastasis of tumor

(2008) Wei Gong et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Interferon-sensitive response element (ISRE) is mainly responsible for IFN-α-induced upregulation of programmed death-1 (PD-1) in macrophages

(2008) Hae-Yun Cho et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection

(2008) Xicheng Wang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection

(2008) Nattawat Onlamoon et al.   IMMUNOLOGY

Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor–induced Behavioral Deficits

(2008) Gwendalyn D King et al.   MOLECULAR THERAPY

Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells

(2008) L. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA